drugset / Trial / NCT00566098

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

NCT00566098

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer cells when they are put back in the body. This may be an effective treatment for patients undergoing a stem cell transplant for multiple myeloma. PURPOSE: This phase I/II trial is studying the side effects of activated white blood cells and to see how well they work in treating patients who are undergoing a stem cell transplant for newly diagnosed stage II or stage III multiple myeloma.

Timeline

Start
2007-11
Primary completion
2014-06
Completion
2018-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MILs Cell therapy
Subject Prevnar 13 Vaccine
Background Melphalan Small molecule 100 mg/m2 Intravenous

Indications